u/Taz9w1

Recently tolvpatan went generic, and apparently the cost is not nearly as exorbitant, therefore I have been prescribing it left and right for my SIADH patients (after starting them in the hospital of course, which is off topic but also a ridiculous rule given that one can start much higher doses of Jynarque outpatient for pckd). I feel like Otsuka could have made bank for the past 10-12 years if they simply lowered the price of the drug outpatient. It was a major cost-prohibitive barrier, and resulted in countless rehospitalizations for hyponatremia. This condition is far more common than PCKD (at least in my experience). Thoughts?